Lack of effect of mild or moderate hepatic impairment on the pharmacokinetics of rimonabant.

被引：0
|
作者：
Grandison, Monica K. [1 ]
Kanamaluru, Vanaja [1 ]
Bishai, Raafat [1 ]
Lockwood, Graham [1 ]
Newton, John [1 ]
机构：
[1] Sanofi Aventis, Malvern, PA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2007年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
74
引用
收藏
页码：1199 / 1199
页数：1
相关论文
共 50 条
  • [21] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF TASOCITINIB (CP-690,550)
    Lawendy, N.
    Chan, G.
    Wang, R.
    Lamba, M.
    Krishnaswami, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S93 - S94
  • [22] Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen
    Yan, Jing-He
    Taylor, Amanda
    Clough, Timothy
    Burmeister-Getz, Elise
    Pazdirkova, Marketa
    Russo, Cesare
    CIRCULATION, 2024, 150
  • [23] Effect of orlistat on the pharmacokinetic of rimonabant.
    Turpault, S
    Woolfrey, S
    Lockwood, GF
    Bishai, R
    Bonnet, D
    Newton, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P77 - P77
  • [24] Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate
    Snell, P
    Dave, N
    Wilson, K
    Rowell, L
    Weil, A
    Galitz, L
    Robson, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 598 - 601
  • [25] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [26] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [27] Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole
    Bramer, S
    Shoaf, S
    Salazar, D
    Mallikaarjun, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S333 - S333
  • [28] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [29] The Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Tofacitinib, an Orally Active Janus Kinase Inhibitor
    Lawendy, Nervin
    Lamba, Manisha
    Chan, Gary
    Wang, Rong
    Alvey, Christine W.
    Krishnaswami, Sriram
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 421 - 427
  • [30] The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor
    Nenad Sarapa
    Margaret R. Britto
    Michelle B. Mainka
    Kourosh Parivar
    European Journal of Clinical Pharmacology, 2005, 61 : 247 - 256
12345